Introduction
Micro-RNAs (miRNAs) are small, endogenous non-coding RNAs that post-transcriptionally regulate gene expression through partial base-pairing with the 3'-untranslated region of target mRNAs, resulting in mRNA destabilization and translational inhibition (1, 2) . These molecules regulate many biological processes, such as cell differentiation, proliferation, apoptosis, and have been implicated in cancers and leukemias (3, 4) . The overexpression of miRNAs can perturb normal hematopoiesis, as first identified by Chen et al (5) . The involvement of miRNAs in hematological malignancies was initially suggested in chronic lymphocytic leukemia (CLL) (6) . Subsequent expression profiling studies identified miRNA signatures characterizing CLL outcome (7, 8) , acute lymphoblastic leukemia (9) and acute myeloid leukemia (AML) associated with various cytogenetic abnormalities (10, 11) . For example, increased expression of miR-155 has been detected in various leukemias and lymphomas (12) , and mice reconstituted with miR-155-expressing bone marrow cells were shown to develop a myeloproliferative disorder (13) . Similarly, over-expression of the miR-17~92 cluster promotes B-cell lymphoma in a mouse model (14) , and mice with increased expression of this cluster in lymphocytes develop lymphoproliferative and autoimmune diseases (15) .
The contribution of miRNAs to the development of, or response to therapy in chronic myeloid leukemia (CML) has not been examined in depth. Venturini et al (16) recently described the increased expression of the miR-17~92 cluster in chronic phase (CP) CML patients that was not found in blast crisis (BC) samples. CML is characterized by the expression of the BCR-ABL fusion gene, resulting from the t(9;22) (q34;q11) translocation. Through its constitutive tyrosine kinase (TK) activity, Bcr-Abl activates a number of signaling pathways which lead to the leukemic phenotype (17) . The TK inhibitor imatinib mesylate (IM) is currently the first line therapy for newly diagnosed CML patients, leading to the rapid clearance of leukemic cells in peripheral blood in >95% of cases (18) . However, a subset of patients do not respond to IM treatment, owing to intolerance or drug resistance.
To identify miRNAs implicated in CML we sought to determine the repertoire of miRNAs expressed in leukemic cells from newly diagnosed patients with CML, prior to and within the first 2 weeks during IM therapy. Using these early time points allowed us to monitor miRNA expression before the leukemic cells became undetectable. We hypothesized that differentially expressed miRNAs would likely play a role in the leukemic cells, and could provide useful novel biomarkers in CML. We used the TaqMan 4 Low Density Array (TLDA) microfluidic system to profile the expression of 365 human mature miRNAs in sequential primary CML samples. This analysis led to the identification of several miRNAs modulated in vivo by IM, which displayed increased (miR-150, miR-146a) or decreased expression (miR-142-3p, miR-199b-5p) after the start of IM therapy as compared to pre-treatment levels. These miRNAs were also differentially expressed in an additional cohort of CML CP patients, and we showed for the first time that the expression of miR-150 was reduced in BC samples as well.
Furthermore, we found significant positive and negative correlations between miRNA expression levels and clinical data before treatment. We discuss candidate target genes for these miRNAs, of relevance in CML. 
Design and Methods

Patient samples
Blood samples were obtained from 10 CML patients in the Clinical Investigation Centre (CIC) -INSERM 802 at Poitiers University Hospital (Table 1) . Samples were collected at diagnosis or on the day before the start of IM treatment (day 0), and when available, within 24 hours after the initiation of IM therapy (day 1), and after one week (day 7) and two weeks (day 14) of IM therapy. One additional patient (P06), for whom no pre-treatment sample was available, was included in this set, using miRNA expression data obtained at day 1 to estimate the expression fold change at day 14. However this patient was not used for the correlation analyses with pre-treatment clinical data. IM was administered at a standard dose of 400 mg each day, at fixed hours. Additional blood or bone marrow samples were obtained from CML patients at diagnosis prior to IM treatment or in blast crisis, as well as from healthy volunteer donors. 
Statistical analysis
The significance of fold change in miRNA expression was analyzed using the Wilcoxon signed rank test applied to the Ct values. MiRNA differential expression analysis between unrelated samples was conducted using the 2-tailed Mann-Whitney U test, and correlation analyses were computed using the Spearman rank correlation test. Analyses were performed using GraphPad Prism v.5 (La Jolla, CA, USA) and SAS v.9 (Cary, NJ, USA) Software. Results with a p-value < 0.05 were considered significant.
Target gene prediction analysis TargetScan 5.0 (19) was searched amongst conserved predictions for genes targeted by highly expressed miR-142-3p, miR-199b-5p, or both, but neither by lowly expressed miR-146 nor miR-150, and vice-versa.
Results
Identification of differentially expressed miRNAs in primary cells from CML patients treated with imatinib
Screening of miRNA expression using the TLDA system was initially performed on 4 patients who had samples taken at day 0, day 1, day 7 and day 14 of IM treatment (Table 1 ). In order to validate the TLDA data from these patients, previously characterized miRNAs from the miR-17~92 cluster on chromosome (Chr) 13 as well as its paralogous clusters, miR-106a~363 on Chr X and miR-106b~25 on Chr 7, were examined (16) . Of the 13 miRNAs analyzed, 11 were consistently detected in all samples, most of which displayed a slightly reduced expression after the first day of IM treatment ( Figure 1A ). A transient increase in expression for some of these miRNAs was noted at day 7, resulting essentially from atypical expression data in a single sample, that was not observed in the other 3 samples. By day 14, ten miRNAs showed a variable reduction in expression level compared to day 0. We selected 3 of these miRNAs and confirmed their reduced expression at day 1 and day 14
by quantitative (q)RT-PCR ( Figure 1B ). Altogether, these data suggest that expression of the miR-17~92 cluster in vivo is decreased upon IM therapy, in line with the previous in vitro study, thus providing an internal validation for our TLDA analysis.
We demonstrated the consistent expression of 141 mature miRNAs across all samples out of a possible 365 represented on the TLDA analysis. Fifty-two miRNAs (37%) showed log 2 variations of >0.6 (i.e. >1.5-fold change) in expression from day 0 to day 14, of which 44 were decreased and 8
increased by day 14 (online supplementary Table S1 ). We selected a set of 18 miRNAs for further analysis ( Figure 1C ), based upon their averaged fold change in expression (log 2 variations >0.6 at day 14; miR-18, -32, -98, -132, -148a, -199b-5p, -301a, -374a, -422b; see Table S1) Figure 2A and Table S3 ).
To further assess how these changes in miRNA expression differed from normal levels, we used the Ct values to determine which miRNAs were significantly differentially expressed in CML samples compared to PBMC samples obtained from 6 healthy donors (controls). The expression levels of miR-150 and miR-146a, which are strongly correlated in leukemic cells (Table S4) , showed a progressive increase from day 0 to day 14, with highest levels in control samples ( Figure 2B ). Indeed, at day 14, miR-146a expression was no longer signficantly different from controls. Conversely, while miR-142-3p
and miR-199b-5p expression levels were strongly correlated (Table S4) , they displayed a progressive decrease in expression from day 0 to day 14 samples, with the lowest levels found in controls ( Figure   2C ). In both cases, there was a significant difference in their expression levels between day-0 CML and control samples. Furthermore, expression of miR-145, but not miR-143, was significantly different between day 0 samples and controls, although these two miRNAs displayed a similar decrease in their expression pattern from day 0 to day 14 ( Figure 2D ). Finally, the small difference in miR-181a expression between day 0 samples and controls was statistically significant, whereas variations displayed by miR-18 and miR-148a were of borderline significance (not shown).
Overall these results demonstrate a significantly increased expression of miR-150 and miR-146a, and a decrease in miR-142-3p, miR-199b-5p, and miR-145 expression, in peripheral blood cells in newly diagnosed CML patients after treatment with IM. Our data also demonstrate that their aberrant expression in leukemic cells tends towards, or reaches normal control values after 14 days IM treatment.
Correlation between miRNA expression levels and clinical data White blood cell counts (WBC) before IM treatment strongly correlated with miR-143, miR-145 and with miR-199b-5p expression levels (P<0.001, P<0.01 and P<0.05 respectively, Table 2, ) . An inverse correlation was observed between the WBC and miR-150 expression at day 0. These results suggest that low expression levels of miR-150, and high expression levels of miR-143/miR-145/miR-199b-5p reflect the high leukocyte counts found in newly diagnosed CML patients. Platelet levels at day 0 were strongly associated with miR-181a and miR-18 levels (P<0.01), as well as miR-155 (P<0.05). The hemoglobin level at day 0 correlated with miR-27 and miR-148a expression (P<0.01, Table 2 ).
Importantly, there was no correlation between miRNA expression changes and the variations in lymphocyte vs neutrophil composition at these 2 time points, suggesting that the observed changes in miRNA expression do not reflect changes in peripheral blood composition (Table S6 ).
Although most of the day 0 samples were collected after initial diagnosis (Table 1) , we sought to examine whether miRNA expression levels correlated with the Sokal risk score (21) . Analysis of the clinical features at day 0 and diagnosis revealed that 9 out of 10 patients exhibited similar blood cell counts at these two time points, whereas the last patient displayed large variations in WBC (patient P11, Table 1 ). Given that, as shown above, the expression of some miRNAs correlated with the WBC,
we performed the correlation analysis on the remaining 9 patients only, and found that miR-142-3p correlated to the Sokal score (Table 2 ). This result suggests that miR-142-3p expression levels at diagnosis could be used for prognostic purposes in CML.
Furthermore, miR-18 fold change between day 0 and day 14 inversely correlated to the time before the occurrence of a first complete hematological response (r=-0.7198, P=0.0125). Curiously, this miRNA is decreased in patients treated with IM. This may indicate that the rapid inhibition of miR-18 is detrimental to an early hematological remission. Finally, although only four patients in this study presented with blasts in peripheral blood at diagnosis (Table 1) , this group of patients showed higher levels of miR-142-3p and miR-199b-5p expression, compared to the group without blasts (not shown).
Analysis of differentially expressed miRNAs in a separate CML test set
We showed that a number of miRNAs were significantly differentially expressed between pretreatment CML patients and healthy donors. This raised the question whether these miRNAs were consistently differentially expressed in CML as compared to normal cells, which would be indicative of a more direct role for these miRNAs in leukemic cells. We therefore measured the expression level of selected miRNAs by qRT-PCR in samples from an additional 12 CML patients, including 6 patients at diagnosis before IM treatment (chronic phase, CP) and 6 in blast crisis (BC), including 2 patients who relapsed after IM. miR-150 expression was significantly reduced by ~30-fold in both CP and BC patients as compared to normal cells ( Figure 3A) , and miR-146a expression was significantly reduced in CP samples ( Figure 3B ). On the other hand, miR-142-3p and miR-199b-5p displayed a significantly higher expression in CP, but not BC samples, compared to controls (Figure 3C-D) . miR-145 and miR181a expression was not significantly different between CP, BC, and control groups (not shown).
These results confirmed the consistent reduction in expression of miR-150 and miR-146a, and increased expression of miR-142-3p and miR-199b-5p in CML samples at diagnosis, and showed that low expression of miR-150 was maintained in BC phase.
Target gene prediction analysis
In order to provide insights regarding genes of relevance for CML that could be targeted by the miRNAs identified in our study, we searched for predictions using TargetScan 5.0 (19), considering genes simultaneously targeted by the highly expressed miR-142-3p and miR-199b-5p, but not by miR-146a and miR-150, and vice-versa (Table 3 ). This approach relies on our recent observation that miRNA targets are often targeted at multiple sites (22) , which substantially enhances the specificity of predictions. Putative target genes of miR-142-3p and miR-199b-5p included ARGHEF12, MAP3K11, and MYH9, while the complementary analysis identified 2 known genes putatively co-targeted by miR146a and miR-150, including the metalloproteinase gene MMP16. Searching for genes targeted by any individual miRNA but not the other 2 (e.g. genes targeted by miR-146a or miR-150, but not by miR-142-3p nor miR-199b-5p) resulted in larger numbers of candidate genes (Table S5) .
Discussion
In this study, we analyzed the expression profile of miRNAs in patients newly diagnosed with CML undergoing upfront therapy with IM. Of 141 mature miRNAs consistently detected, 52 were differentially expressed by more than 1.5-fold, most of which exhibited reduced expression by day 14 of IM therapy compared to pre-treatment samples. We demonstrated the significantly increased expression of miR-150 and miR-146a, and decreased expression of miR-142-3p and miR-199b-5p in
PBMCs of CML patients after 14 days of IM treatment. Expression levels of miRNAs tended to normalize to levels seen in non-leukemic PBMCs by day 14 of IM treatment. The changes in miRNA expression are likely attributable to the leukemic cells, since after 2 weeks of IM therapy, only one patient had achieved complete hematological remission (Table 1) . Therefore we identified miRNAs that are modulated in vivo by IM in CML patients.
We found that miR-150, miR-146a, miR-142-3p and miR-199b-5p consistently exhibited aberrant expression in an additional group of patients with CML at diagnosis compared to healthy subjects.
This raises the possibility that these miRNAs could be involved in Bcr-Abl-mediated leukemogenesis, at diagnosis compared to healthy subjects. This is consistent with our data demonstrating decreased expression of miR-150 in CML samples, and increased expression of miR-151 and miR-10a by day 14 following IM treatment (Table S1 ). These data suggest that the aberrant expression of miR-150, miR-146a, miR-142-3p and miR-199b-5p identified in our study likely plays a role in leukemic cells, and potentially in the more primitive hematopoietic compartment in chronic phase CML patients.
stimulation, suggesting their involvement in the regulation of the immune system (24). Since we found an increased expression in both miR-132 and miR-146a by day 14 of IM treatment (Table S1) , their reduced expression in CML cells could play a role in impairing an immune response against CML cells. Also of interest was the increased expression of miR-215 and miR-192 after IM treatment.
These miRNAs were recently shown to be increased by p53 in diverse settings, and to contribute to subsequent cell cycle arrest (25) . Given that IM treatment induced p53 expression in BCR-ABLexpressing cells (26) , it is therefore possible that miR-215 and miR-192 could play a role in IMinduced, p53-mediated cell cycle regulation of CML cells.
miRNA expression levels before treatment correlated with various clinical parameters, including WBC, platelet counts and hemoglobin levels ( Table 2 ). In addition, we found a correlation between miR-142-3p expression level in CML patients and the Sokal risk score at diagnosis. Expression of both miR-150 and miR-146a was consistent for all but one patient ( Figure 2A) . In contrast to the other 10 patients, this patient exhibited decreased expression of these miRNAs by day 14 of IM treatment compared to day 0. Interestingly, this patient was the only one who ceased IM treatment after 4 months, having achieved complete hematological remission, because of the occurrence of acute hepatitis. Although it is only one case, it will be of interest to determine whether measuring miR-150
and miR-146a expression as early as within the first 2 weeks of IM therapy could be indicative of IM intolerance later on. Of note, this patient was included in the TLDA analysis, which may explain, at least in part, the high heterogeneity observed in the miRNA expression results.
We identified several genes predicted to be targets of both miR-142-3p and miR-199b-5p, and neither miR-146a nor miR-150 (and vice-versa), that are known to be involved in hematopoiesis or leukemia, including ARHGEF12, MAP3K11, and MYH9. The Rho guanine nucleotide exchange factor gene ARHGEF12 (also known as LARG) was first identified as a fusion partner for MLL in acute myeloid leukemia (27) . MAP3K11 encodes a serine/threonine kinase involved in the activation of both the p38 MAPK and JNK signaling pathways (28) . This gene was shown to interact functionally with BCR-ABL in fibroblast and hematopoietic cell transformation (29) . The gene MYH9 encodes a non-muscle myosin heavy chain which is up-regulated in myeloid cells upon differentiation (30) and is mutated in several hematopoietic disorders (31) . Genes putatively co-targeted by miR-146a and miR-150
included MMP16/MT3-MMP, which encodes a metalloproteinase that confers basement membrane 14 transmigration ability to cancer cells (32) . Of note, it was recently suggested that miR-146b, another member of the miR-146 family, targeted MMP16 in the human U373 glioma cells (33) .
In addition to these predictions, a number of genes have already been validated as being targeted by these miRNAs. Specifically, miR-150 targets the oncogene MYB (34, 35) , which encodes a transcription factor that is often over-expressed in hematological malignancies, including CML (36) .
Furthermore, in a mouse model of CML blast crisis, it was recently found that c-Myb was required for
Bcr-Abl-dependent leukemogenesis (37) . Interestingly, over-expression of miR-150 in K562 CML cells strongly inhibits c-MYB protein expression (35) . It is thus possible that c-Myb upregulation induced by Bcr-Abl may be mediated, at least in part, by the reduced expression of miR-150. miR-146 was recently shown to negatively regulate the NF-B pathway by inhibiting the expression of IRAK1 and TRAF6 (24, 38) . NF-B transcriptional activity is constitutively activated by Bcr-Abl and mediates BcrAbl-induced transformation in cell lines and primary cells (39, 40) . Furthermore, inhibition of NF-B activity induces apoptosis of BCR-ABL-expressing cells (41) . This suggests that reduced expression of miR-146a could be involved in the constitutive activation of NF-B signaling induced by Bcr-Abl, thereby contributing to its transforming and anti-apoptotic activity. In support of these ideas, both MYB and TRAF6 were identified in our target gene prediction analysis as not being targeted by either miR-142-3p or miR-199b-5p (Table S5) . miR-199b-5p was recently reported to negatively regulate the Notch pathway in meduloblastoma cells by inhibiting the Notch target gene HES1, leading to reduced cell proliferation (42) . Interestingly, constitutive activation of Notch in K562 cells was shown to inhibit cell proliferation and colony-forming activity, along with increased HES1 mRNA levels (43) . It is therefore possible that the increased expression of miR-199b-5p could play a role in the inhibition of Notch signaling in CML cells, contributing to their increased proliferative activity.
In summary, IM treatment results in a relatively rapid increase in the expression of miR-150 and miR146a, and decreased expression of miR-142-3p and miR-199b-5p in PBMCs of patients newly diagnosed with CML. We showed that the aberrant expression level of these miRNAs was tending towards normal levels after only 2 weeks of IM therapy. These miRNAs, by regulating certain predicted and known target genes, may be involved in Bcr-Abl-driven leukemogenesis. Upper part shows genes predicted by TargetScan 5.0 to be co-targeted by miR-142-3p AND miR-199b-5p, with no target sites for miR-146a nor miR-150. Lower part shows predictions using the opposite miRNA combination. 
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